GDRX · GoodRx Holdings, Inc.
$2.95
+0.08 (+2.79%)
At close · Jul 24
Market Cap
$1.00B
Shares
338.68M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$796.85M
+0.6%
FY2025
Net Income
$30.44M
+85.7%
FY2025
Operating Margin
10.98%
+2.7pp
FY2025
Diluted EPS
$0.09
+125%
FY2025
Operating Cash Flow
$167.9M
-8.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $787.89M | $796.85M | $792.32M | $750.27M | $766.55M | $745.42M | $550.7M | $388.22M | $249.52M | |
| $120.06M | $121.03M | $123.75M | $135.84M | $143.14M | $125.86M | $61.82M | $29.3M | $43.89M | |
| $328.07M | $331.56M | $367.11M | $341.33M | $357.63M | $370.22M | $255.14M | $176.97M | $104.18M | |
| $111.15M | $113.96M | $117.86M | $125.52M | $144.79M | $154.69M | $461.45M | $14.69M | $8.36M | |
| — | $11.9M | $8.8M | $59M | $23.2M | $18.3M | $12.7M | $11.2M | $9.1M | |
| $86.1M | $85.22M | $69.54M | $107.67M | $54.18M | $34.54M | $18.43M | $13.57M | $9.81M | |
| $709.77M | $709.36M | $726.48M | $777.27M | $764.82M | $732.02M | $826.42M | $248.55M | $172.27M | |
| $78.12M | $87.49M | $65.85M | -$27.01M | $1.74M | $13.41M | -$275.72M | $139.68M | $77.25M | |
| — | 10.98% | 8.31% | -3.6% | 0.23% | 1.8% | -50.07% | 35.98% | 30.96% | |
| $164.22M | $172.71M | $135.38M | $80.66M | $55.92M | $47.95M | -$257.29M | $153.25M | $87.06M | |
| $41.73M | $42.61M | $52.92M | $56.73M | $34.24M | — | — | — | — | |
| -$32.61M | -$30.95M | -$34.39M | -$28.57M | -$24.97M | -$23.58M | -$27.73M | -$56.7M | -$24.9M | |
| $45.51M | $56.54M | $31.46M | -$55.57M | -$23.23M | -$10.18M | -$303.45M | $82.98M | $52.35M | |
| $24.95M | $26.1M | $15.07M | -$46.7M | $9.6M | $15.08M | -$9.83M | $16.93M | $8.56M | |
| $20.56M | $30.44M | $16.39M | -$8.87M | -$32.83M | -$25.25M | -$293.62M | $66.05M | $43.79M | |
| — | 3.82% | 2.07% | -1.18% | -4.28% | -3.39% | -53.32% | 17.01% | 17.55% | |
| — | — | — | — | — | -$25.25M | -$293.62M | $42.44M | $13.8M | |
| — | — | — | — | — | $0 | $0 | $0 | — | |
| USD/shares | — | $0.09 | $0.04 | -$0.02 | -$0.08 | -$0.06 | -$1.07 | $0.19 | $0.12 |
| USD/shares | — | $0.09 | $0.04 | -$0.02 | -$0.08 | -$0.06 | -$1.07 | $0.18 | $0.12 |
| shares | — | 356.33M | 385.74M | 410.32M | 412.86M | 409.98M | 274.7M | 226.61M | 111.84M |
| shares | — | 356.97M | 392.17M | 410.32M | 412.86M | 409.98M | 274.7M | 231.21M | 118.34M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2025: $580.91M in buybacks, $1.35B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.59×
Health Information Services median 1.33×
EV/EBIT
16.05×
Health Information Services median 25.09×
P/E (TTM)
49.33×
Health Information Services median 33.02×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Prescription Transactions Revenue | $544,001,000 | $577,549,000 | $550,738,000 | $550,536,000 | $593,359,000 | $488,257,000 | $364,582,000 |
| Pharma Direct Revenue | $151,380,000 | $107,237,000 | $85,065,000 | — | — | — | — |
| Subscription Revenue | $83,786,000 | $86,536,000 | $94,410,000 | $96,167,000 | $59,925,000 | $29,386,000 | $13,085,000 |
| Other Revenue | $17,686,000 | $21,002,000 | $20,052,000 | $20,426,000 | $18,792,000 | $12,569,000 | $10,557,000 |
| Pharma Manufacturer Solutions Revenues | — | — | — | $99,425,000 | $73,348,000 | $20,488,000 | — |
Key facts
CIK
1809519
CUSIP
38246G108
13F (30d)
23 filings
23 filers
Visit website
Investor relations